Royal Bank of Canada
KNSA icon

Royal Bank of Canada’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Royal Bank of Canada’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12K Buy
249
+162
+186% +$7.18K ﹤0.01% 6102
2025
Q4 		$3K Sell
87
-374
-81% -$15K ﹤0.01% 6834
2025
Q3 		$18K Sell
461
-222,747
-100% -$7.24M ﹤0.01% 6251
2025
Q2 		$6.17M Buy
223,208
+220,746
+8,966% +$5.62M ﹤0.01% 2405
2025
Q1 		$55K Buy
2,462
+568
+30% +$11.7K ﹤0.01% 5532
2024
Q4 		$38K Sell
1,894
-3,277
-63% -$74.8K ﹤0.01% 5827
2024
Q3 		$129K Buy
5,171
+551
+12% +$13.4K ﹤0.01% 5166
2024
Q2 		$87K Buy
4,620
+2,793
+153% +$52.3K ﹤0.01% 5351
2024
Q1 		$36K Sell
1,827
-9,761
-84% -$191K ﹤0.01% 5672
2023
Q4 		$203K Buy
11,588
+4,535
+64% +$74.5K ﹤0.01% 5090
2023
Q3 		$123K Buy
7,053
+3,530
+100% +$59.5K ﹤0.01% 5243
2023
Q2 		$50K Buy
3,523
+1,080
+44% +$14.5K ﹤0.01% 5781
2023
Q1 		$27K Sell
2,443
-2,263
-48% -$29.8K ﹤0.01% 5912
2022
Q4 		$71K Buy
4,706
+4,072
+642% +$59.3K ﹤0.01% 5694
2022
Q3 		$8K Buy
634
+208
+49% +$2.37K ﹤0.01% 6535
2022
Q2 		$4K Sell
426
-1,615
-79% -$15.1K ﹤0.01% 6728
2022
Q1 		$20K Sell
2,041
-4,582
-69% -$48.5K ﹤0.01% 6606
2021
Q4 		$78K Buy
6,623
+3,673
+125% +$45.1K ﹤0.01% 6107
2021
Q3 		$34K Buy
2,950
+704
+31% +$9.17K ﹤0.01% 6383
2021
Q2 		$31K Sell
2,246
-1,255
-36% -$19.1K ﹤0.01% 6322
2021
Q1 		$64K Buy
3,501
+1,470
+72% +$30.1K ﹤0.01% 5735
2020
Q4 		$35K Buy
2,031
+864
+74% +$15.2K ﹤0.01% 5807
2020
Q3 		$18K Buy
1,167
+1,025
+722% +$19.2K ﹤0.01% 5733
2020
Q2 		$3K Buy
142
+94
+196% +$1.96K ﹤0.01% 6183
2020
Q1 		$1K Sell
48
-1,148
-96% -$18K ﹤0.01% 6448
2019
Q4 		$13K Buy
+1,196
New +$10.4K ﹤0.01% 6049
2019
Q1 		– Sell
-145
Closed -$4K – 6954
2018
Q4 		$4K Sell
145
-85
-37% -$1.77K ﹤0.01% 6228
2018
Q3 		$6K Buy
+230
New +$4.47K ﹤0.01% 6188

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Royal Bank of Canada's KNSA Position: Q1 2026 in Review

Royal Bank of Canada increased its Kiniksa Pharmaceuticals (KNSA) stake by 186% in Q1 2026, buying an estimated $7.18K and bringing the position to 249 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #6102.

Royal Bank of Canada first reported a position in KNSA in Q3 2018 and has held it in 28 quarters since. The position peaked at $6.17M in Q2 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Royal Bank of Canada held 249 shares of Kiniksa Pharmaceuticals worth $12K as of Q1 2026.
  • Royal Bank of Canada bought 162 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $7.18K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6102 holding.
  • Royal Bank of Canada first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 28 quarters since.
  • Royal Bank of Canada's Kiniksa Pharmaceuticals position peaked at $6.17M in Q2 2025.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.